|
Stories from the dialysis comunity across the globe.
|
|
Low-dose dopamine or nesiritide of no help in acute heart failure. |
 |
 |
|
Mayo Clinic: In the Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE-AHF) randomized 26-site trial in the U.S. and Canada, researchers analyzed data on 360 hospitalized acute heart failure patients with kidney dysfunction from September 2010 to March 2013. Compared to placebo, researchers found that neither dopamine nor nesiritide, when also used with diuretic (water pills) therapy, was better at increasing urine volume or improving levels of serum cystatin-C, an indicator of kidney function, at the end of a 72-hour treatment.
|
|
|
Eveolocumab lowers LDL cholesterol in patients with marked hypercholesterolemia. |
|
|
|
Amgen: The 52-week open label study, showed that monthly treatment Evolocumab reduced cholesterol levels up to 52 percent in combination with SOC in patients with high cholesterol, and also prevented major increase in adverse events. Meanwhile, 81.4 percent of patients showed adverse events including nasopharyngitis, upper respiratory tract infections, influenza, arthralgia, and back pain. Other minor reported events include muscle-problems, elevated liver function, elevated creatine kinase.
|
|
Abatacept slows or halts proteinuria in FSGS. |
|
|
|
Med Page Today (ASN): Proteinuria resolved partly or completely in a small group of patients with focal segmental glomerulosclerosis (FSGS) treated with abatacept (Orencia), according to a study reported here.
|
|
|
VA NEPHRON D Sttudy in NEJM: Combination ACE-I and ARB treatment for diabetic nephropathy with proteinuria found to be harmful. |
|
|
|
NEJM: Conclusions. Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy
|
|
CORAL study reports negative results in the NEJM re stenting of renovascular HTN. |
|
|
|
NEJM: Conclusions Renal-artery stenting did not confer a significant benefit with respect to the prevention of clinical events when added to comprehensive, multifactorial medical therapy in people with atherosclerotic renal-artery stenosis and hypertension or chronic kidney disease.
|
|
|
|
|
<< Start < Prev 421 422 423 424 425 426 427 428 429 430 Next > End >>
|
|
Page 421 of 4210 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
